Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles
Open Access
- 18 July 2016
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 23 (9) , 3505-3519
Abstract
Oxaliplatin is one of the chemotherapeutic agents in the first line therapy for treatment of colorectal cancer. But, limitations of chemotherapy affects the clinical applicability of oxaliplatin depriving its activity at targeted site attributed to the lack of site specificity. This limitation paves the way for undesirable toxic effects to healthy cells resulting in sub-standard drug amount at the tumors obliging for increased dose. The present study emphasizes on formulating gold nanoparticles encapsulating oxaliplatin and later conjugating with anti-DR5 antibody for improved anti-cancer activity in a synergistic and site-specific manner. Oxaliplatin immuno-nanoparticles (Co-Ox-AuNPs) had shown sustained release and confirmed by fluorescence and flow cytometry studies. MTT assay exhibited 3-fold decrease in cell viability of nanoparticles comparable to oxaliplatin. Triple fluorescence method employed in HCT 116 and MCF-7 cells justified its site specificity. Annexin-propidium iodide (PI) and Acridine orange-ethidium bromide assays further supported the apoptotic activity. Moreover, caspase-dependent molecular mechanism behind oxaliplatin induced anti-cancer activity was explored by western blot analysis. Reduction in tumor size and volume in xenograft tumor models justified its in vitro activity. Oxaliplatin side effects were analyzed in mice and were confirmed for their clinical efficacy highlighting our formulation as an alternative to chemotherapy.Keywords
This publication has 36 references indexed in Scilit:
- Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of OxaliplatinJournal of the American Chemical Society, 2010
- Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swineNanomedicine: Nanotechnology, Biology and Medicine, 2009
- Active targeting schemes for nanoparticle systems in cancer therapeuticsAdvanced Drug Delivery Reviews, 2008
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- Paclitaxel-Functionalized Gold NanoparticlesJournal of the American Chemical Society, 2007
- Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathwayThe International Journal of Biochemistry & Cell Biology, 2007
- Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in Colon Cancer CellsJapanese Journal of Clinical Oncology, 2005
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosisInternational Journal of Cancer, 2002
- Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4The Journal of Immunology, 2001